BACKGROUND: Providers of external quality assurance (EQA)/proficiency testing schemes have traditionally focused on evaluation of measurement procedures and participant performance and little attention has been given to reagent lot variation. The aim of the present study was to show the importance of reagent lot registration and evaluation in EQA schemes. METHODS: Results from the Noklus (Norwegian Quality Improvement of Primary Care Laboratories) urine albumin/creatinine ratio (ACR) and prothrombin time international normalized ratio (INR) point-of-care EQA schemes from 2009 -2015 were used as examples in this study.
One of the tools in total quality management of medical laboratories is to participate in external quality assurance (EQA) 3 /proficiency testing programs (1 ) , and it has been shown that participation over time has the potential to improve participant performance (2 ) . In principle, the laboratories receive control samples with, for them, unknown target values, measure the control samples within a certain time period, report the results to the EQA organizer together with information about their method, and receive feedback about their performance (3 ) . In addition to being used to evaluate the performance of each single participant, results from EQA schemes can also be used to evaluate the performance of measurement procedures when commutable control materials are used. Depending on the category of EQA schemes (4 ), different target values can be established, e.g., reference method target values, overall participant mean or median target values, and method-specific peer group target values.
As far as possible, EQA organizations should use control materials that reflect native patient samples. A control material is considered commutable when the numeric relation between 2 methods is the same with the control material as it is as for patient samples (5 ) . When commutable materials with common target values are used for all methods, interlaboratory variation can in principle be caused by variation between measurement procedures, variation between reagent lots, and variation between participant performance. With the use of noncommutable material with peer group target values, the interlaboratory variation within one measurement procedure can be explained by lot-to-lot variation and participant performance. In EQA, focus has usually been on variation between measurement procedures and participant performance, but to our knowledge little has been published on lot-to-lot variation, although a few exceptions exist (6, 7 ) . One of the reasons could be that reagent lots are probably not commonly registered in EQA.
The Norwegian Quality Improvement of Primary Care Laboratories (Noklus) has registered and evaluated results from reagent lots in all their schemes since 1992.
For many analytes, commutable control material is not obtainable and noncommutable materials are commonly used (8 ) . It is often taken for granted that noncommutable control materials are commutable within one measurement procedure, i.e., "commutable between lots," indicating that the differences between reagent lots found using the control material also will be valid for patient samples. This is, however, not always the case (7 ) .
The aim of the present study was to show examples of lot-to-lot variation in EQA schemes and to discuss the importance of this information.
Materials and Methods

EQA SCHEME FOR POINT-OF-CARE URINE ALBUMIN AND
ALBUMIN/CREATININE RATIO
Two control samples were distributed once a year until 2013, when the frequency was increased to twice a year. The control material was pooled urine from persons with normal and increased excretion of albumin. The albumin concentration in the distributed urine controls varied from 25 to 114 mg/L during the period from 2009 to 2015. The urine samples were collected before each survey and stored less than 1 month at Ϫ80°C before being thawed, sterile filtered, and circulated to the participants. To see if this frozen urine control material gave similar results to those of fresh native urine, 1 of the control samples in the first survey in 2014 (1/2014) was not stored frozen but was collected, sterile filtered, and stored in the refrigerator the day before distribution. The participants analyzed the control samples in duplicate and reported the results within 1 week. The samples were homogeneous and stable during this period, according to ISO 13528 (9 ) . Several different types of point-of-care (POC) instruments were used by the participants, but the most common were the DCA systems (DCA 2000, DCA 2000ϩ, DCA Vantage) (Siemens) and the Afinion system (Afinion AS100 Analyzer) (Alere). In the period from 2009 to 2015, the number of participants decreased from 513 to 472 for DCA and increased from 350 to 496 for Afinion. The response rate was about 90% in each survey and the participants were mainly general practitioner (GP) offices. The participants reported the reagent lot number used and the expiration date in addition to the albumin, creatinine, and albumin/creatinine ratio (ACR) results.
EQA SCHEME FOR POC PROTHROMBIN TIME INTERNATIONAL
NORMALIZED RATIO
In the regular EQA scheme, 2 control samples were distributed twice a year. The types of control materials used were dependent on the type of POC instruments. For users of the CoaguChek XS systems (CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro) (Roche Diagnostics) a commercial liquid pooled human plasma from patients on anticoagulation treatment with warfarin was used from 2013. The controls were delivered frozen by the manufacturer (Nordic Hemostasis AB) and on the distribution day, the material was thawed and circulated to the participants. The liquid EQA materials could be used without any reconstitution or recalcification. The participants analyzed the 2 control samples in duplicate and reported the results within 1 week. The material was stable according to ISO 13528 (9 ) . The participants reported the reagent lot number used and the expiration date in addition to the international normalized ratio (INR) results. The number of CoaguChek participants increased from 1106 in 2013 to 1477 in 2015, and the response rate was about 90% in each survey.
To evaluate if the commercial EQA control material gave the same lot-to-lot variation as native patient samples, results from a split-sample survey carried out in parallel with the second EQA survey in 2014 (2/2014) were used for comparison. Twenty-five GP offices that obtained a "very good" performance evaluation in the 2 previous EQA surveys (2/2013 and 1/2014), and in addition were recommended by the Noklus laboratory advisers were selected to participate in the split-sample survey. In total, 108 capillary patient samples were measured on CoaguChek XS Plus by the 25 selected GP offices. Citrated whole blood samples from the same patients were sent to Noklus and analyzed immediately on a designated comparison method (STA Evolution, SPAϩ reagent) (Stago) at Haraldsplass Deaconess Hospital (Bergen). Four common CoaguCheck reagent lots were used by the participants in both surveys and these results were used to evaluate whether the EQA control material was "commutable between lots." For further description of the principle of this split-sample model, see Stavelin et al. (10 ) .
STATISTICS
In the regular EQA schemes, the mean of duplicate measurements for each participant was used to calculate the between-participant variation after exclusion of outliers (3 SD). The target value was the median of all the results within 1 method group, i.e., method-specific peer group target value, after exclusion of outliers. In the INR splitsample survey, the target value was zero, meaning that there ideally should be no difference between the Coagu-Chek results and the hospital comparison method results.
Reagent lots with 5 or more participants were included in the lot evaluation in each survey. The median value with 95% CI for each reagent lot was calculated to evaluate lot-to-lot differences. Results from deviant lots were not excluded from the calculation of the target value. In all figures, the lot numbers are arranged in in-creasing order from low numbers (the oldest) to high number (the newest).
Results
EQA SCHEME FOR POC URINE ALBUMIN AND ACR
The between-participant CV for DCA and Afinion ACR in the surveys from 2009 to 2015 is shown in Fig. 1A . The CV for the Afinion ACR was stable around 6%-7% until the consecutive surveys 1/2013, 2/2013, and 1/2014, during which it increased to about 11%. This increase could not be seen for the DCA instruments. The results for the Afinion albumin showed a similar increase in CV as seen for the ACR, whereas the creatinine results were stable (Fig. 1B) . Small or negligible differences be-tween the Afinion albumin lots were seen in the surveys before 2013, as shown for the 2011 survey (Fig. 2 ). In the consecutive surveys 1/2013, 2/2013, and 1/2014, larger differences between reagent lots were observed, as exemplified for the 2/2013 survey (Fig. 2 ). In later surveys (2/2014 and 1/2015), the differences between reagent lots decreased. The same lot-to-lot variation was seen using both fresh control samples and frozen control samples in the same survey (1/2014) ( Fig. 3) , and the between-participant CV was 11.1% for both the fresh and frozen urines in this survey. An overview of Afinion albumin reagent lot-to-lot variation from 2009 to 2015 is shown in Fig. 1 , A-I, in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol62/issue5. 2 ). There was a tendency for the lot medians to increase as a function of the production date of the lots. The median for each reagent lot that was represented in more than one survey did not increase, or increased only slightly, from one survey to another ( Fig. 4) , indicating that each lot itself was stable over time. The lot differences found using the EQA control material were not observed when native patient samples were used ( Fig. 5 ).
Discussion
Here we report 2 examples of lot-to-lot variation detected in EQA schemes for POC ACR and for POC INR, respectively, for which the interpretation and consequences of the findings were different. The lot-to-lot differences found for the Afinion ACR were also valid for patient samples and thus had consequences both for the interpretation of the EQA results and for the reported patient results. In contrast, the lot-to-lot differences found for CoaguCheck INR using a commercial EQA material could not be reproduced when fresh patient samples were used. The CoaguChek reagent lot variation had therefore no consequences for the reported patient results, but was important for the correct interpretation of the EQA results. If reagent lots had not been registered in these cases, important information for the EQA organizer, the participants, and the manufacturers would not have been obtained.
For the ACR scheme, an increase in the betweenparticipant CV was observed for the Afinion system in 3 consecutive surveys ( Fig. 1A) owing to an increase in between-participant variation in albumin (Fig. 1B) . This increase was explained by a large lot-to-lot variation between several Afinion albumin reagent lots in use, as exemplified for the 2/2013 survey (Fig. 2) . It is reasonable to believe that these lot-to-lot differences also affected patient results, because a fresh urine sample distributed together with the frozen urine sample in one of the surveys showed similar results (Fig. 3 ). In addition, the between-participant variation was the same for the frozen and fresh urine in this survey. Thus, the frozen control material could be characterized as "commutable between lots." This conclusion is supported by earlier findings in which it has been shown that freezing below Ϫ70°C has a negligible effect on urine albumin concentrations (11, 12 ) . Noklus informed the participants using the deviant reagent lots about the systematic deviations from the target value, and that patient results could be affected. The results were also communicated to the manufacturer, who reported that the reagents had not been stored adequately during that period due to a change of warehouse. When the storage condition was corrected, both the lot variation and the between-participant variation decreased. If reagent lots had not been registered in this scheme, the reason for the increased between-participant CV would not have been known, the participants would not have received information in the feedback report that could explain their deviant EQA results, and the manufacturer may not have detected the wrong storage conditions of the reagents.
The clinical impact of reagent lot-to-lot variation is largest around medical decision limits. The largest lot differences found in the ACR scheme were 1.8 and 3.8 mg/mmol at ratios of 8 and 15 mg/mmol, respectively (survey 2/2013), and the between-participant CV was 11% at both levels (Fig. 1 ). If such lot differences were also present at the medical decision limit of 3 mg/mmol, this could have clinical implications in the categorization of the patients. Clinically important lot deviations that could affect patient results should be communicated to clinicians who treat the patients. The communication with clinicians will usually be the responsibility of the EQA participants who receive the EQA feedback report, but the responsibility to state if patient results potentially could have been affected is the responsibility of the EQA providers. The EQA providers should seek to distribute control samples with concentrations around clinically important decision limits.
For the INR scheme using commercial control samples, an increase in target value was seen in surveys using the same batch of control material ( Fig. 4 ; also see online Supplemental Fig. 2) , indicating a shift in INR level for the CoaguChek instruments. The manufacturer reported that they had changed the composition of the test strips starting from lot H during this period (2014 -2015) . The new strips (lot H, I, and J) gave higher INR results than other lots when the commercial EQA material was used ( Fig. 4 ). However, there was a tendency for the lot medians to increase as a function of the production date even before this change in strip composition (Fig. 4) . This increase was not due to instability of the lots because each lot median did not increase, or increased only slightly over time (Fig. 4, reagent lots D, E, F, G, H, and I) . The tendency of increasing INR results with increasing lot numbers found in the EQA scheme using a commercial control material could not be seen in the split-sample survey using patient samples (Fig. 5 ). This observation indicates that the control material was not "commutable between lots." The participants were informed about the systematic deviation from the target value of their reagent lot because this could explain possible deviant EQA results when the problem was reagent lot-specific noncommutability of the EQA control materials. At the same time, it was clarified that using different reagent lots did not affect patient results. If reagent lots had not been registered in this scheme, the changed reagent strip composition would probably have been communicated to the participants as a possible explanation for the increased target values, wrongly indicating that there had been a The split sample and EQA surveys were carried out at the same time. shift in INR values for the CoaguChek instruments. In addition, if the split-sample survey with native patient samples had not been performed in parallel to the EQA scheme, the reagent lot results could have been misinterpreted as reagent lot differences in patient samples.
It is well known that when the control material is not commutable between measurement procedures, the EQA results cannot be used to evaluate systematic differences between measurement procedures, and methodspecific target values have to be used (4 ) . However, one should take into account that the EQA materials also can be noncommutable between reagent lots in the same measurement procedure, as shown for INR in this study. Therefore in such cases, if large differences between reagent lots are present, lot-specific target values should be considered to avoid giving some participants wrong evaluations (7 ) . As an example: for the high INR level with a target value of 4.50 INR in survey 2/2014, one of the reagent lots (lot E) had a median INR value of 3.85 INR, which was outside the lower limit of acceptable performance (3.92 INR) , meaning that at least half of the participants using this lot were evaluated as "poor." The method-specific target value was the mean of all results and thus dominated by results from lot H. By using a lot-specific target value, all participants with reagent lot E would have obtained an acceptable or good performance, which would have been a more correct evaluation.
As illustrated by the 2 examples in this study, registration and evaluation of reagent lots in EQA schemes are important for several reasons. It is important for the EQA provider because it adds value to explain the survey results, which can be communicated in the feedback report to the participants as well as to the manufacturers. It is also useful for the participants in the troubleshooting process to locate the source of error when they receive a deviant EQA result. The EQA providers should ideally register and evaluate results from reagent lots in every survey to detect problems with the survey results and to alert participants and manufacturers of important lotspecific defects that cannot otherwise be identified. The reagent lot results do not necessarily have to be included in every feedback report to the participants.
When significant lot variation is detected the participants should be informed about how much their lot deviates from the target value and, if possible, whether this would affect patient samples. In cases in which the lot deviation is also valid for patient samples, the participants may consider changing the reagent lot and revising earlier patient results that might have been affected. When deviant lot results are found, the EQA provider should consider excluding or marking results in the cumulative report to the participants. Information about deviant reagent lots can also be useful for the manufacturers to detect possible problems with the lots (e.g., storage conditions and calibration issues). Based on the results from the lot evaluations the manufacturer may consider withdrawal of lots from the market.
A limitation of this study is that it is possible that some reagent lots on the market were not assessed because of the low scheme frequency of once and twice a year. Ideally, for EQA schemes using control materials that reflect patient samples, the frequency should be high enough to cover all reagent lots on the market. However, it is possible that reagent lot registration is less important in some types of schemes, especially in cases in which reagent lot-to-lot variation is small or nonexistent. However, when noncommutable controls are used there is no way to know if a reagent lot's influence on commutability is present unless the reagent lots are registered.
A strength of this study is that there were a high number of participants in the 2 schemes, meaning that lot-to-lot differences were possible to detect. The lot differences detected with the commercial EQA INR control material did not reflect native patient samples (i.e., was not commutable between reagent lots), and if this finding is observed in future EQA schemes, this control material should not be used. Using EQA control materials that are not commutable between reagent lots will have limited value, confound the EQA providers assessment of results, and only confuse the participants. It is probable that many EQA providers assume that their EQA material is commutable between reagent lots without confirming this assumption with data.
The examples presented in this report illustrate the importance of reagent lot evaluation in EQA. The information about the reagent lot differences is essential for interpretation of the EQA results by EQA providers, participants, and manufacturers. EQA providers are encouraged to register and evaluate results from reagent lots in EQA schemes.
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